Lilly and BI, following their SGLT2 rivals, plot kidney disease study for Jardiance

12th June 2017 Uncategorised 0

Eli Lilly and Boehringer Ingelheim have reason to believe their SGLT2 inhibitor, Jardiance, may be able to improve outcomes for chronic kidney disease patients—so they’re putting the med to the test.

More: Lilly and BI, following their SGLT2 rivals, plot kidney disease study for Jardiance
Source: fierce